Interactive Brokers Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHAD)

Add RCHAD Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, EnergySaver, buythebuy
Search This Board: 
Last Post: 6/25/2017 12:40:34 AM - Followers: 212 - Board type: Free - Posts Today: 2 ;

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#12771  Sticky Note RCHAD FDA Approval News & Must See Videos… stervc 06/22/17 08:43:50 AM
#12535  Sticky Note RCHA Rich Pharmaceuticals' Division CannCodex Releases buythebuy 05/11/17 06:15:24 AM
#12985   True, but this has been 100% share selling Drugdoctor 06/25/17 12:40:33 AM
#12984   Nobody knows the future it's all opinions...RCHAD $$$$ tibt913 06/25/17 12:31:14 AM
#12983   You are.... sigh.... another group of baggies fell Drugdoctor 06/24/17 09:16:12 PM
#12982   I really hope we're all not totally screwed here... masahirox 06/24/17 08:42:25 PM
#12980   Just watch for the 8k filings that always Axeman 06/24/17 03:46:49 AM
#12979   Tuesday will be the day, if it keeps pitacorp 06/23/17 06:30:32 PM
#12978   i am thinking the same, and chart wise, pitacorp 06/23/17 06:24:47 PM
#12977   LOL. Writing was on the wall but u Axeman 06/23/17 05:24:23 PM
#12976   This is a scam!! I should have sold Pstats 06/23/17 04:19:46 PM
#12975   I'm holding! Chrishen05 06/23/17 04:19:28 PM
#12974   I know for sure that a new thrust 1chiarajolie 06/23/17 03:38:46 PM
#12973   I think it's a shake down of flippers. masahirox 06/23/17 03:27:07 PM
#12972   I understand the CEO and his history. I Chrishen05 06/23/17 03:07:21 PM
#12971   Yes, he damn sure has been. GoodiePop 06/23/17 02:28:28 PM
#12970   It is but history here repeats itself with Axeman 06/23/17 02:25:54 PM
#12969   Holding for .01+ when I should have taken Chrishen05 06/23/17 01:51:40 PM
#12968   it is ridiculous. Based on this news of Chrishen05 06/23/17 01:50:53 PM
#12967   Wow 7s after 30s the past 2 days. masahirox 06/23/17 01:47:09 PM
#12966   NO ONE should sell at these levels. It's ridiculous. 1218galatea 06/23/17 01:24:05 PM
#12965   Clinical research and Phase 1 studies have already tibt913 06/23/17 01:16:06 PM
#12964   Yes this is done for today! Going to Pstats 06/23/17 12:24:37 PM
#12963   Deff not running today. I'm not gonna sell masahirox 06/23/17 12:21:58 PM
#12962   .0035 yesterday! .003-0035 23m bought at those levels Pstats 06/23/17 12:05:38 PM
#12961   Look how .0008 was getting hit I put Pstats 06/23/17 11:54:46 AM
#12960   Lmao!!! No one is selling that's all MM Pstats 06/23/17 11:54:09 AM
#12959   NO DILUTION. PROOF? 1218galatea 06/23/17 11:52:01 AM
#12958   1 million at .001 just went through. Alyssa 06/23/17 11:50:14 AM
#12957   why are people selling into the 8s??? masahirox 06/23/17 11:45:23 AM
#12956   RCHA something is shaken here! Could be huge Pstats 06/23/17 11:44:34 AM
#12955   theres no momo here masahirox 06/23/17 11:41:03 AM
#12954   Fast track FDA approval process....RCHAD$$$ tibt913 06/23/17 11:32:33 AM
#12953   RCHAD so a little further investigation VNDM Pstats 06/23/17 11:30:04 AM
#12952   Hoping for no conversions. That is what kills Axeman 06/23/17 11:25:18 AM
#12951   Hopefully it works out. Some decent buying here now. Garyst 06/23/17 11:25:07 AM
#12950   This thing about to explode!! L2 screaming buytime! Pstats 06/23/17 11:17:36 AM
#12949   So hope for 18 to 24 months God FRANKIEJR 06/23/17 11:16:59 AM
#12948   bunch of cheapo $200 flippers here... its has masahirox 06/23/17 11:16:22 AM
#12947   It was fake .004 target Pstats 06/23/17 11:16:14 AM
#12946   Level 2 is funny, a bunch of retail Expensivetaste281 06/23/17 11:14:09 AM
#12945   Fake to sell shares. Scam stockmaster007 06/23/17 11:12:12 AM
#12944   57m BID disappeared hopefully is to do some Pstats 06/23/17 11:12:08 AM
#12943   fake. 1218galatea 06/23/17 11:10:26 AM
#12942   now its 57 mil bid WTF just HAPPENED??? masahirox 06/23/17 11:07:49 AM
#12941   WTF??? ARE YOU SERIOUS??? WOWOW masahirox 06/23/17 11:07:20 AM
#12940   WTH 50M BID??? Pstats 06/23/17 11:06:45 AM
#12939   Trials can take up to a couple of GoodiePop 06/23/17 11:00:20 AM
#12938   Me too. My entry level over a PepsiMan 06/23/17 10:57:27 AM
#12937   Question is How long will trials take and FRANKIEJR 06/23/17 10:56:33 AM
#12936   I invested in this stock to generate revenue GoodiePop 06/23/17 10:56:33 AM
#12935   I feel very confident that once the trials GoodiePop 06/23/17 10:53:38 AM